Non-HPV-16 genotypes linked to poor HNSCC survival
medwireNews: Patients with head and neck squamous cell carcinoma (HNSCC) who harbour human papillomavirus (HPV) genotypes other than HPV-16 have significantly worse overall survival (OS) than those testing positive for HPV-16, suggests an analysis of The Cancer Genome Atlas data.
The 3-year OS rate was 49% for the 12 HNSCC patients with non-HPV-16 genotypes and 88% for the 61 participants who were positive for HPV-16, a significant difference.
Patients with HNSCC associated with genotypes other than HPV-16 “might therefore be inappropriate candidates for treatment deintensification”, say Scott Bratman (Princess Margaret Cancer Centre, Toronto, Ontario, Canada) and colleagues in JAMA Oncology.
They add, however, that prospective confirmation in larger cohorts is required before HPV genotypes can be used to inform treatment decisions.
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016